Us-china Biomedical Technology, Inc. (CLDS) |
|
|
|
Us-china Biomedical Technology Growth Comparisons
Select each growth Category to receive further Information
Select the Comparisons :
|
|
Select the Ratio:
|
|
CLDS's Growth Comparisons in I. Quarter 2019
Us-china Biomedical Technology reported top-line of $ 0 millions in the first quarter 2019, compare to $ 0 millions in the same quarter a year ago. Revenues in the Advertising industry grew by 0.28%, while the top-line in the Services sector increased by 5.71%, and overall market improved by 3.55% from the first quarter 2018. Sequentially company's Revenue were unchanged from the forth quarter results. . Looking into annual growth, sales grew by % on average in last five years, while S & P 500's including only Businesses with the first quarter 2019 earnings reports, average yearly sales growth is 10.54%.
Growth Rates of CLDS's Income in the first quarter 2019
CLDS's EPS Growth Rates
Us-china Biomedical Technology reported bottom-line of $ -0.01 in the first quarter, compare to $ -0.02 in the same quarter a year ago. Advertising industry grew by 6.55%, while Services sector decreased by -13.9%, and overall market declined by -1.56%. Sequentially company's EPS were unchanged from the forth quarter results. . Looking into annual growth, income per share grew by % on average in the last five years, while the S & P 500's including only the businesses with the first quarter 2019 financial results, average yearly income per share growth is 11.57%.
CLDS Cash Flow Growth Rates
|